Subscribe
Models
HUGO Series 🌟
Cell Line Models
Services
Preclinical Efficacy
Resources
About Us
hSARM1 Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
hSARM1 Mouse
Product Name
hSARM1 Mouse
Product ID
C002035
Strain Name
C57BL/6NCya-Sarm1em1(hSARM1)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “hSARM1 Mouse (Catalog C002035) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
Basic Information
Related Resource
Basic Information
Gene Name
SARM1
Gene Alias
SARM, HsTIR, SAMD2, hSARM1, MyD88-5
NCBI ID
Chromosome
Chr 17 (Human)
MGI ID
Datasheet
Strain Description
Sterile alpha and TIR motif-containing protein 1 (SARM1) is a multifunctional NAD⁺ hydrolase encoded by the SARM1 gene and belongs to the TIR domain-containing protein family. SARM1 is highly expressed in the nervous system and is particularly enriched in neuronal axons, where it serves as a central executor in response to neuronal injury, metabolic stress, and multiple neurodegenerative pathological processes [1]. SARM1 functions as a metabolic sensor that specifically recognizes and responds to abnormal elevations in the intracellular nicotinamide mononucleotide (NMN) to NAD⁺ ratio. It plays a critical regulatory role in Wallerian-like programmed axonal death triggered by neuronal injury. This process is closely associated with axonal injury, neurodegenerative diseases such as Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS), as well as chemotherapy-induced peripheral neuropathy (CIPN) [2-4]. Studies have shown that pathogenic or gain-of-function variants of SARM1 can trigger uncontrolled NAD⁺ depletion, neuronal metabolic failure, and axonal degeneration [4]. SARM1 gene knockout or functional inhibition significantly protects axons from degeneration in various neuronal injury models [1]. Owing to its low-to-moderate expression in normal adult tissues and high expression in the nervous system, SARM1 has become an important therapeutic target in the field of neuroprotection. Multiple small-molecule inhibitors targeting SARM1, gene therapy strategies, and related drug candidates have entered preclinical and early clinical development for blocking programmed axonal degeneration and associated neuroinflammatory processes [5-7].
The hSARM1 mouse is a humanized model generated by replacing a partial sequence of exon 1 in the murine Sarm1 gene with the Kozak-Human SARM1 CDS-Human SARM1 3'UTR-WPRE-BGH pA cassette. This model is suitable for the in vivo efficacy and safety evaluation of SARM1-targeted small-molecule inhibitors, antisense oligonucleotides (ASOs), AAV-mediated gene silencing strategies, and other neuroprotective agents. It is also suitable for research on the mechanisms underlying axonal degeneration and neurodegenerative diseases, neuronal metabolic stress, and the regulation of the SARM1-NAD⁺ signaling pathway.
Reference
Osterloh, J. M., et al. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science, 2012 Jul;337(6093):481-484.
Figley, M. D., et al. SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration. Neuron, 2021 Mar;109(7):1118-1136.
Meraner P, Avetisyan A, Swift K. Hypoxia-inducible factor 1 protects neurons from Sarm1-mediated neurodegeneration. Cell Reports, 2026 Jan;45:2
Bloom, A. J., et al. Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients. Molecular Neurodegeneration, 2022 Jan;17(1):1.
Leahey, R.R., Weber, M., Cho, C.H. et al. Therapeutic safety implications of SARM1 active site inhibitors: subinhibitory concentrations cause neurodegeneration. npj Drug Discovery,2025 Aug;21:2
Peter Arthur-Farraj, Andrea Loreto, Targeting SARM1: from inhibition for neuroprotection to activation for neuroablation, Trends in Pharmacological Sciences, 2025 Nov;46(11):1105-1116,
Liu P, Chen W, Jiang H. et al. Differential effects of SARM1 inhibition in traumatic glaucoma and EAE optic neuropathies. Mol Ther Nucleic Acids, 2023 Feb;32:13-27.
Strain Strategy
The partial exon 1 coding region of mouse Sarm1 gene was replaced with the Kozak-Human SARM1 CDS-Human SARM1 3'UTR-WPRE-BGH pA cassette.

Figure 1. Gene editing strategy of hSARM1 mice.
Application Area
Screening, development, and preclinical evaluation of SARM1-targeted therapeutics;
Research on neurodegenerative diseases, including Alzheimer's disease (AD);
Therapeutic research on axonal degeneration;
Development of SARM1-targeted small-molecule inhibitors;
Research on SARM1 gene silencing therapeutic strategies.
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

